Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 15, 2018. The report discloses a specific transaction under the company's Deferred Investment Award Programme involving a Person Discharging Managerial Responsibilities (PDMR).
Key Financial Metrics
The filing does not provide consolidated financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on a specific equity-related transaction.
| Metric | Value |
|---|---|
| Transaction Type | Restricted award of notional Ordinary Shares |
| Instrument | Ordinary Shares of 25 pence each (ISIN: GB0009252882) |
| Volume | 90,266.667 notional shares |
| Price | £15.00 per share |
| Transaction Date | February 14, 2018 |
Material Changes
The filing reports the grant of a notional share award to Mr. L. Miels, President of Global Pharmaceuticals, who joined the company in September 2017. This is an initial notification of the award and does not represent a material change in the company's overall financial position or operations.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on market outlook, or discussion of general corporate risks. The specific terms of the award include:
- Vesting Schedule: 25% of the award vests annually on September 4, 2020, 2021, 2022, and 2023.
- Conditions: Vesting is contingent on the PDMR remaining employed and not being terminated for cause.
- Payout: Notional dividends accrue via reinvestment; the final award and accrued dividends are paid in cash upon vesting.
- Eligibility: Executive Directors are explicitly excluded from this programme.
Key Facts for Investor Verification
- Verify the total number of notional shares granted (90,266.667) and the associated price (£15.00) in the context of the company's broader compensation strategy.
- Confirm the vesting timeline (2020–2023) and the cash-settlement nature of the award.
- Note that this filing is a regulatory disclosure of a specific executive compensation event and does not contain quarterly or annual financial performance data.